Sareum Holdings plc (AIM:SAR)

London flag London · Delayed Price · Currency is GBP · Price in GBX
15.50
-4.40 (-22.11%)
Oct 10, 2025, 5:15 PM GMT+1
-22.11%
Market Cap21.40M
Revenue (ttm)n/a
Net Income (ttm)-2.83M
Shares Out138.07M
EPS (ttm)-0.03
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,862,547
Average Volume637,933
Open10.00
Previous Close19.90
Day's Range9.50 - 18.00
52-Week Range9.00 - 32.00
Beta-1.74
RSI18.98
Earnings DateOct 24, 2025

About Sareum Holdings

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company’s lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also involves in developing SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor, which h... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 5
Stock Exchange London Stock Exchange AIM
Ticker Symbol SAR
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.